Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003

Journal of Clinical Oncology

Volumn 23, Issue 36, 2005, Pages 9097-9104

  Williamson, Stephen K ^a   Crowley, John J ^a   Lara Jr , Primo N ^a   McCoy, Jason ^a   Lau, Derick H M ^a   Tucker, Robert W ^a   Mills, Glenn M ^a   Gandara, David R ^a   Granados, Bonnie ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; TIRAPAZAMINE; ANTINEOPLASTIC AGENT; TRIAZINE DERIVATIVE;

ABDOMINAL CRAMP; ADULT; ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEARING LOSS; HUMAN; HYPOTENSION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT RESPONSE; VISUAL DISORDER; VOMITING; CELL HYPOXIA; DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIAZINES;

EID: 33644817804     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.3771     Document Type: Article

References (37)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005
2. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909, 1995
3. Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough? J Clin Oncol 11:1866-1872, 1993
4. Klastersky J, Paesmans M: Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer. Review of literature results. Lung Cancer 34: S95-S101, 2001 (suppl 4)
5. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 16:2459-2465, 1998
6. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999
7. Arriagada R, Bergman B, Dunant A, et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360, 2004
8. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001
9. Brown JM: SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67:1163-1170, 1993
10. Durand RE, Olive PL: Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat Oncol Investig 5:213-219, 1997
11. Brown JM, Wang LH: Tirapazamine: Laboratory data relevant to clinical activity. Anticancer Drug Des 13:529-539, 1998
12. Dorie MJ, Brown JM: Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53:4633-4636, 1993
13. Holden SA, Teicher BA, Ara G, et al: Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma. J Natl Cancer Inst 84:187-193, 1992
14. Siim BG, Menke DR, Dorie MJ, et al: Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: Relationship to tumor hypoxia. Cancer Res 57:2922-2928, 1997
15. Treat J, Johnson E, Langer C, et al: Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 16:3524-3527, 1998
16. von Pawel J, von Roemeling R, Gatzemeier U, et al: Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group-Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol 18:1351-1359, 2000
17. Gandara DR, Lara PN Jr, Goldberg Z, et al: Tirapazamine: Prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol 29:102-109, 2002 (suppl 4)
18. Shepherd FA, Koschel G, von Pawel J, et al: Comparison of Tirazone (tirapazamine) and cisplatin vs. etoposide and cisplatin in advanced non-small cell lung cancer (NSCLC): Final results of the international phase III CATAPULT II Trial. Lung Cancer 29:28, 2000 (suppl 1, abstr 87)
19. Weitman S, Mangold G, Marty J, et al: Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Cancer Chemother Pharmacol 43:402-408, 1999
20. Lara PN Jr, Frankel P, Mack PC, et al: Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: A California cancer consortium phase I and molecular correlative study. Clin Cancer Res 9:4356-4362, 2003
21. Tozawa K, Yamada Y, Kawai N, et al: Osteopontin expression in prostate cancer and benign prostatic hyperplasia. Urol Int 62:155-158, 1999
22. Shijubo N, Uede T, Kon S, et al: Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 160:1269-1273, 1999
23. Koong AC, Denko NC, Hudson KM, et al: Candidate genes for the hypoxic tumor phenotype. Cancer Res 60:883-887, 2000
24. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
25. National Cancer Institute: Common Toxicity Criteria (version 2). http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf
26. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
27. Brookmeyer R, Crowley J: A confidence interval for the median survival time. Biometrics 38:29-41, 1982
28. Crowley J, Breslow N: Statistical analysis of survival data. Annu Rev Public Health 5:385-411, 1984
29. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
30. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
31. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
32. Galvin IV, Lara PN, Le Q, et al: Hypoxia-induced proteins in plasma of patients on the Southwest Oncology Group (SWOG) S0003 trial in advanced non-small cell lung carcinoma (NSCLC). Proc of Am Soc of Clin Oncol 22:667, 2003 (abstr 2684)
33. Galvin IV, Lara PN, Le Q, et al: Hypoxia-related markers in the plasma of patients with advanced non-small cell lung cancer (NSCLC) and survival from chemotherapy: Southwest Oncology Group (SWOG) S0003. J Clin Oncol 22:649, 2004 (suppl, abstr 7146)
34. De Jaeger K, Merlo FM, Kavanagh MC, et al: Heterogeneity of tumor oxygenation: Relationship to tumor necrosis, tumor size, and metastasis. Int J Radiat Oncol Biol Phys 42:717-721, 1998
35. Brizel DM, Dodge RK, Clough RW, et al: Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53:113-117, 1999
36. Fyles AW, Milosevic M, Pintilie M, et al: Cervix cancer oxygenation measured following external radiation therapy. Int J Radiat Oncol Biol Phys 42:751-753, 1998
37. Nordsmark M, Overgaard J: A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 57:39-43, 2000